MX2017011902A - Derivados de heteroarilo biciclico fusionado que tienen actividad como inhibidores del dominio de prolil hidroxilasa. - Google Patents

Derivados de heteroarilo biciclico fusionado que tienen actividad como inhibidores del dominio de prolil hidroxilasa.

Info

Publication number
MX2017011902A
MX2017011902A MX2017011902A MX2017011902A MX2017011902A MX 2017011902 A MX2017011902 A MX 2017011902A MX 2017011902 A MX2017011902 A MX 2017011902A MX 2017011902 A MX2017011902 A MX 2017011902A MX 2017011902 A MX2017011902 A MX 2017011902A
Authority
MX
Mexico
Prior art keywords
activity
bicyclic heteroaryl
fused bicyclic
heteroaryl derivatives
phd inhibitors
Prior art date
Application number
MX2017011902A
Other languages
English (en)
Spanish (es)
Inventor
Kinsella Natasha
Livermore David
Canning Hannah
Davenport Richard
Wright Susanne
Ahmed Saleh
Barker Gregory
Harrison David
Jenkins Kerry
Original Assignee
Takeda Pharmaceuticals Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceuticals Co filed Critical Takeda Pharmaceuticals Co
Publication of MX2017011902A publication Critical patent/MX2017011902A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/04Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D519/00Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Epidemiology (AREA)
  • Plural Heterocyclic Compounds (AREA)
MX2017011902A 2015-03-18 2016-03-17 Derivados de heteroarilo biciclico fusionado que tienen actividad como inhibidores del dominio de prolil hidroxilasa. MX2017011902A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1504565.1A GB201504565D0 (en) 2015-03-18 2015-03-18 Novel compounds
PCT/JP2016/059782 WO2016148306A1 (en) 2015-03-18 2016-03-17 Fused bicyclic heteroaryl derivatives having activity as phd inhibitors

Publications (1)

Publication Number Publication Date
MX2017011902A true MX2017011902A (es) 2017-12-15

Family

ID=53051992

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017011902A MX2017011902A (es) 2015-03-18 2016-03-17 Derivados de heteroarilo biciclico fusionado que tienen actividad como inhibidores del dominio de prolil hidroxilasa.

Country Status (31)

Country Link
US (1) US10287286B2 (enExample)
EP (1) EP3271357B1 (enExample)
JP (1) JP6726681B2 (enExample)
KR (1) KR102609431B1 (enExample)
CN (1) CN107531698B (enExample)
AU (1) AU2016234209B2 (enExample)
BR (1) BR112017019653B1 (enExample)
CA (1) CA2979024C (enExample)
CL (1) CL2017002354A1 (enExample)
CO (1) CO2017009353A2 (enExample)
CR (1) CR20170468A (enExample)
DK (1) DK3271357T3 (enExample)
DO (1) DOP2017000209A (enExample)
EA (1) EA035739B1 (enExample)
EC (1) ECSP17069696A (enExample)
ES (1) ES2774052T3 (enExample)
GB (1) GB201504565D0 (enExample)
GE (2) GEP20207095B (enExample)
HU (1) HUE047918T2 (enExample)
IL (1) IL254277B (enExample)
MX (1) MX2017011902A (enExample)
MY (1) MY194873A (enExample)
NZ (1) NZ735631A (enExample)
PE (1) PE20180656A1 (enExample)
PH (1) PH12017501699B1 (enExample)
PT (1) PT3271357T (enExample)
SG (1) SG11201707280VA (enExample)
TN (1) TN2017000384A1 (enExample)
UA (1) UA123668C2 (enExample)
WO (1) WO2016148306A1 (enExample)
ZA (1) ZA201706612B (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3712153B1 (en) 2016-02-24 2021-12-01 Pfizer Inc. Pyrazolo[1,5-a]pyrazin-4-yl derivatives as jak-inhibitors
EP3668858A1 (en) 2017-08-14 2020-06-24 Pfizer Inc Pyrazolo[1,5-a]pyrazin-4-yl and related derivatives
CA3106385A1 (en) * 2018-09-13 2020-03-19 Kissei Pharmaceutical Co., Ltd. Imidazopyridinone compound
CN110950806A (zh) * 2019-11-14 2020-04-03 安庆博曼生物技术有限公司 四乙基氯化铵催化嘧啶环羟基氯代制备方法
JP7504822B2 (ja) * 2020-03-12 2024-06-24 キッセイ薬品工業株式会社 イミダゾピリジノン化合物を含む医薬組成物
US11718622B2 (en) 2020-03-16 2023-08-08 Exelixis Inc. Heterocyclic adenosine receptor antagonists
CN117304171A (zh) * 2020-04-20 2023-12-29 深圳市塔吉瑞生物医药有限公司 吡嗪取代的烟酰胺的固体形式及其制备和用途
EP4232444A4 (en) * 2020-10-20 2024-09-11 Amgen Inc. HETEROCYCLIC SPIRO COMPOUNDS AND METHODS OF USE
US12492178B2 (en) 2021-09-01 2025-12-09 Empathbio, Inc. Stable polymorph of R-MDMA HCl
WO2023072240A1 (en) 2021-10-28 2023-05-04 Insilico Medicine Ip Limited Prolyl hydroxylase domain-containing protein (phd) inhibitors and uses thereof
WO2023111990A1 (en) * 2021-12-17 2023-06-22 Akebia Therapeutics, Inc. Selective phd1 inhibitor compounds, compositions, and methods of use
US11912680B2 (en) 2021-12-28 2024-02-27 Empathbio, Inc. Nitric oxide releasing prodrugs of MDA and MDMA

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4209621A (en) 1979-04-27 1980-06-24 American Cyanamid Company (Substituted-phenyl)-1,2,4-triazolo[4,3-a]-pyrimidines and (substituted-phenyl)-1,2,4-triazolo[1,5-a]pyrimidines
DK135184A (da) * 1983-03-03 1984-10-10 Riker Laboratories Inc Triazol(4,3-c)- og triazol(1,5-c)pyrimidiner
US4572910A (en) * 1983-03-03 1986-02-25 Riker Laboratories, Inc. Triazolo[1,5-c]pyrimidines substituted by nitrogen-containing heterocyclic rings
PL360027A1 (en) 2000-06-30 2004-09-06 Wyeth Substituted-triazolopyrimidines as anticancer agents
JP2010065026A (ja) 2008-08-13 2010-03-25 Ishihara Sangyo Kaisha Ltd ピリジル−トリアゾロピリミジン誘導体又はその塩、並びにそれらを含有する有害生物防除剤
JP2010065024A (ja) 2008-08-14 2010-03-25 Ishihara Sangyo Kaisha Ltd トリアゾロピリミジン誘導体又はその塩を含有する有害生物防除剤
SG178049A1 (en) * 2009-07-17 2012-03-29 Japan Tobacco Inc Triazolopyridine compound, and action thereof as prolyl hydroxylase inhibitor and erythropoietin production inducer
JP2011168582A (ja) * 2010-01-21 2011-09-01 Ishihara Sangyo Kaisha Ltd トリアゾロピリジン誘導体又はその塩、それらの製造方法及びそれらを含有する有害生物防除剤
US20150239889A1 (en) 2012-08-23 2015-08-27 Mitsubishi Tanabe Pharma Corporation Pyrazolopyrimidine compound

Also Published As

Publication number Publication date
HK1249512A1 (en) 2018-11-02
CR20170468A (es) 2018-04-27
SG11201707280VA (en) 2017-10-30
JP2018512408A (ja) 2018-05-17
BR112017019653B1 (pt) 2023-10-03
GB201504565D0 (en) 2015-05-06
PH12017501699B1 (en) 2023-06-30
US20180072714A1 (en) 2018-03-15
WO2016148306A1 (en) 2016-09-22
AU2016234209A1 (en) 2017-10-12
JP6726681B2 (ja) 2020-07-22
TN2017000384A1 (en) 2019-01-16
CL2017002354A1 (es) 2018-05-04
CA2979024C (en) 2024-02-20
GEAP201914608A (en) 2019-10-10
CN107531698A (zh) 2018-01-02
IL254277B (en) 2020-10-29
UA123668C2 (uk) 2021-05-12
ECSP17069696A (es) 2018-02-28
EA035739B1 (ru) 2020-08-03
CO2017009353A2 (es) 2017-11-30
ZA201706612B (en) 2019-01-30
MY194873A (en) 2022-12-21
KR102609431B1 (ko) 2023-12-04
KR20170129874A (ko) 2017-11-27
EA201792057A1 (ru) 2018-04-30
PE20180656A1 (es) 2018-04-17
EP3271357A1 (en) 2018-01-24
IL254277A0 (en) 2017-10-31
EP3271357B1 (en) 2019-11-27
DOP2017000209A (es) 2017-10-15
PT3271357T (pt) 2020-02-21
BR112017019653A2 (pt) 2018-05-15
DK3271357T3 (da) 2020-02-17
ES2774052T3 (es) 2020-07-16
CA2979024A1 (en) 2016-09-22
AU2016234209B2 (en) 2020-08-27
NZ735631A (en) 2023-07-28
HUE047918T2 (hu) 2020-05-28
GEP20207095B (en) 2020-04-10
US10287286B2 (en) 2019-05-14
CN107531698B (zh) 2024-08-13
PH12017501699A1 (en) 2018-03-12

Similar Documents

Publication Publication Date Title
CO2017009353A2 (es) Derivados de heteroarilos bicíclicos fusionados con actividad como inhibidores de phd
MX2018003432A (es) Compuestos heterociclicos y usos de los mismos.
SV2017005514A (es) Derivados de nucleósidos sustituidos útiles como agentes antineoplásicos
MX2020011449A (es) Oxiesteroles y metodos de uso de los mismos.
MX389349B (es) Derivados de ácido borónico y usos terapéuticos de los mismos.
MX2017013886A (es) Azabenzimidazoles y su uso como moduladores del receptor ampa.
CR20150371A (es) Inhibidores de prmt5 y sus usos
CO2017013708A2 (es) Macrociclos peptídicos contra acinetobacter baumannii.
ECSP16074478A (es) Compuestos novedosos
MX2016014547A (es) Compuestos para tratar atrofia muscular espinal.
MX376271B (es) Compuestos heterocíclicos y usos de los mismos.
MX2018000280A (es) Oxiesteroles y metodos de uso de los mismos.
DOP2014000036A (es) Compuestos de piridazinona y su uso como inhibidores daao
CO2018002211A2 (es) Piridinona dicarboxamida para su uso como inhibidores de bromodominio
CU20180028A7 (es) DERIVADOS DE IMIDAZO[4,5-b]PIRIDINA, ÚTILES COMO INHIBIDORES DUALES DE DYRK1/CLK1 Y COMPOSICIONES FARMACÉUTICAS QUE LOS CONTIENEN
CL2017002498A1 (es) Piridopirimidinonas y su uso como modulares del receptor nmda
ECSP16074482A (es) Ciclopentanos, tetrahidrofuranos y pirrolidinas sustituidas como antagonistas del receptor de orexina
ECSP18056196A (es) Derivados de indano
AR132461A2 (es) Derivados de piperidinil-indol como inhibidores del factor de complemento b y usos de los mismos
UY35672A (es) Derivados de amino-metil-biarilo como inhibidores del factor de complemento d y usos de los mismos

Legal Events

Date Code Title Description
FG Grant or registration